Page 15 - Exact Sciences News Today

New York State Common Retirement Fund trimmed its holdings in shares of Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 14.8% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 339,704 shares of the medical research company’s stock after selling 59,061 shares during […]

Milestone Investment Advisors LLC bought a new position in shares of Exact Sciences Co. (NASDAQ:EXAS – Free Report) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 842 shares of the medical research company’s stock, valued at approximately $57,000. Other hedge funds and other […]

Exact Sciences Corp. , a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its fourth quarter 2023 financial results after the close of the...

Objective To explore how the number and type of breast cancers developed after screen detected atypia compare with the anticipated 11.3 cancers detected per 1000 women screened within one three year screening round in the United Kingdom. Design Observational analysis of the Sloane atypia prospective cohort in England. Setting Atypia diagnoses through the English NHS breast screening programme reported to the Sloane cohort study. This cohort is linked to the English Cancer Registry and the Mortal...

Shares of Exact Sciences Co. (NASDAQ:EXAS – Get Free Report) have been given a consensus rating of “Moderate Buy” by the sixteen ratings firms that are presently covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating and fourteen have issued a buy rating on the company. The average […]

The 23rd annual Best of Madison Business Awards honor visionary leaders who see how it all connects to build a better Madison.

Exact Sciences Co. (NASDAQ:EXAS – Get Free Report) has been given an average rating of “Moderate Buy” by the sixteen research firms that are presently covering the stock, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and fourteen have assigned a buy recommendation to the company. The average 12-month price objective […]

Olaparib plus abiraterone acetate delayed disease progression and improved outcomes in patients with BRCA-, ATM- and CDK12-mutated mCRPC.

Dublin, Jan. 25, 2024 (GLOBE NEWSWIRE) -- The

A passerby lead a life-saving rescue effort to remove a driver from his burning vehicle early Wednesday.